Sigma Labs, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Tables)

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2020

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per

At September 30, 2020 and 2019, the Company had the following common shares underlying these instruments:

	September 30,
	2020		2019
Warrants		1,845,722		362,061
Preferred Stock Warrants		260,089		-
Stock Options		610,229		125,103
Preferred Stock		227,695		-
Convertible Note Payable		-		2,500

Total Underlying Common Shares		2,943,735		489,664

Schedule of Earnings Per Share, Basic and Diluted

The following data shows the amounts used in computing loss per share and the effect on income and the weighted average number of shares of dilutive potential common stock for the periods ended September 30, 2020 and 2019:

	Three Months Ended September 30						Nine Months Ended September 30
	2020			2019			2020			2019

Net Loss per Common Share - Basic and Diluted	$	(0.42	)	$	(1.20	)	$	(1.74	)	$	(4.30	)
Loss from continuing
Operations available to Common stockholders (numerator)	$	(1,955,357	)	$	(1,600,794	)	$	(5,455,707	)	$	(4,678,397	)

Weighted average number of common shares Outstanding used in loss per share during the Period (denominator)		4,675,749			1,285,160			3,137,459			1,099,627